The Antisecretory Effects of RP 40 749 in Patients with Previous Duodenal Ulcer

J. Myren Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

R. Stave Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

J. Mosvold Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

L. E. Hanssen Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

P. Linnestad Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

M. Osnes Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

S. Larsen Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

A. Berstad Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

K. Valnes Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

S. Lorentzenlund Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

A. Rosetzsky Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

A. Frydman Section of Gastroenterology, Dept. of Medicine, Ullevål University Hospital, Oslo, Norway; Dept. of Medicine, Lovisenberg Hospital, Oslo, Norway; Laboratory of Immunohistochemistry and Immunopathology, Rikshospitalet, The National Hospital, Oslo, Norway; Rhône-Poulenc, Skårer, Norway; Medical Dept., Rhône-Poulenc Pharraa Norden A/S, Birkerød, Denmark; Institute of Biopharmacy, Rhône-Poulenc Santé, Paris, France

show all

Abstract

Thirteen male patients with a history of duodenal ulcer were given 150 mg RP 40 749 or placebo tablets at bedtime in a double-blind crossover study. The medication was given for two periods of 10 days with an 11-day wash-out period between. pH and pepsin concentrations were determined each hour in aspirates of gastric juice for 24 h on day 1, 10, 22, 31, and a 2-h collection of gastric juice was examined in the middle of the treatment and wash-out periods. At defined hours blood samples were examined for gastrin, somatostatin, and pancreatic polypeptide (PP) by radio-immunological methods, and concentrations of RP 40 749 were determined in blood and gastric juice. Meals were served at fixed hours on days 1, 10, 22, and 31. After treatment with RP 40 749 a highly significant elevation of pH was found after the 1st day compared with placebo, most pronounced during night hours. The pepsin activity was slightly elevated. The serum concentrations of gastrin were increased and those of somatostatin and PP decreased during the first 3–4 h after medication, with a subsequent normalization. No side effects were observed.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The Antisecretory Effects of RP 40 749 in Patients with Previous Duodenal Ulcer

Information for

Open access

Opportunities

Help and information

The Antisecretory Effects of RP 40 749 in Patients with Previous Duodenal Ulcer

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature